SI3250554T1 - Derivat karboksiamida in njegovi diastereomeri v stabilni kristalinični obliki - Google Patents

Derivat karboksiamida in njegovi diastereomeri v stabilni kristalinični obliki

Info

Publication number
SI3250554T1
SI3250554T1 SI201631571T SI201631571T SI3250554T1 SI 3250554 T1 SI3250554 T1 SI 3250554T1 SI 201631571 T SI201631571 T SI 201631571T SI 201631571 T SI201631571 T SI 201631571T SI 3250554 T1 SI3250554 T1 SI 3250554T1
Authority
SI
Slovenia
Prior art keywords
diastereomers
crystalline form
stable crystalline
carboxamide derivative
carboxamide
Prior art date
Application number
SI201631571T
Other languages
English (en)
Slovenian (sl)
Inventor
Olli Tormakangas
Terhi Heikkinen
Original Assignee
Orion Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55349869&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3250554(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corporation filed Critical Orion Corporation
Publication of SI3250554T1 publication Critical patent/SI3250554T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SI201631571T 2015-01-30 2016-01-28 Derivat karboksiamida in njegovi diastereomeri v stabilni kristalinični obliki SI3250554T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20150033 2015-01-30
EP16704029.4A EP3250554B1 (en) 2015-01-30 2016-01-28 A carboxamide derivative and its diastereomers in stable crystalline form
PCT/FI2016/050054 WO2016120530A1 (en) 2015-01-30 2016-01-28 A carboxamide derivative and its diastereomers in stable crystalline form

Publications (1)

Publication Number Publication Date
SI3250554T1 true SI3250554T1 (sl) 2022-09-30

Family

ID=55349869

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201631571T SI3250554T1 (sl) 2015-01-30 2016-01-28 Derivat karboksiamida in njegovi diastereomeri v stabilni kristalinični obliki

Country Status (14)

Country Link
US (4) US10010530B2 (enExample)
EP (1) EP3250554B1 (enExample)
JP (2) JP7283861B2 (enExample)
CY (1) CY1125482T1 (enExample)
DK (1) DK3250554T3 (enExample)
ES (1) ES2917549T3 (enExample)
HR (1) HRP20220998T1 (enExample)
HU (1) HUE058986T2 (enExample)
LT (1) LT3250554T (enExample)
PL (1) PL3250554T3 (enExample)
PT (1) PT3250554T (enExample)
RS (1) RS63477B1 (enExample)
SI (1) SI3250554T1 (enExample)
WO (1) WO2016120530A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6716023B2 (ja) * 2016-08-26 2020-07-01 クリスタル ファーマシューティカル（スーチョウ）カンパニー，リミテッド アンドロゲン受容体拮抗薬の結晶形及びその製造方法並びに用途
CN108218908A (zh) * 2016-12-15 2018-06-29 连云港润众制药有限公司 一种新型雄激素受体拮抗剂的制备方法
CN121181479A (zh) 2017-03-07 2025-12-23 奥赖恩公司 结晶药物产品的制备
CN110944979B (zh) * 2017-08-09 2023-05-12 杭州领业医药科技有限公司 Odm-201晶型及其制备方法和药物组合物
CN107602471B (zh) * 2017-09-22 2021-04-27 成都恒汇化成医药科技有限公司 一种达罗鲁胺的晶型制备方法
JP2021515040A (ja) * 2018-02-27 2021-06-17 サンド・アクチエンゲゼルシヤフト ダロルタミドの結晶形態ｉｉ
WO2021001603A1 (en) 2019-07-02 2021-01-07 Orion Corporation Pharmaceutical composition of darolutamide
CN110590668A (zh) * 2019-07-17 2019-12-20 江苏君若医药有限公司 N-[(1s)-2-[3-(3-氯-4-氰基苯基)-1h-吡唑-1-基]-1-甲基乙基]-5-(1-羟基乙基)- 1h-吡唑-3-甲酰胺的制备方法
CN110452123B (zh) * 2019-08-30 2021-10-29 南京师范大学 一步构建c-c、c-n、c-s键的合成方法
CN111116476A (zh) * 2019-12-27 2020-05-08 武汉九州钰民医药科技有限公司 制备抗肿瘤药物多拉米胺的方法
WO2022036782A1 (zh) * 2020-08-18 2022-02-24 拜耳消费者护理股份有限公司 一种雄激素受体拮抗剂药物的晶型csvi及其制备方法和用途
WO2022049075A1 (en) 2020-09-02 2022-03-10 Bend Research, Inc. Amorphous solid dispersion of darolutamide
WO2022144926A1 (en) * 2020-12-31 2022-07-07 Msn Laboratories Private Limited, R&D Center Process for the preparation of amorphous n-{(2s)-1-[3-(3-chloro-4-cyanophenyl)-1h-pyrazol-1-yl]propan-2-yl}-5-(1-hydroxyethyl)-1h-pyrazole-3-carboxamide
EP4486727B1 (en) 2022-02-28 2026-02-25 Química Sintética, S.A. Crystalline form of darolutamide
WO2025229051A1 (en) 2024-05-03 2025-11-06 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with antiandrogen agent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
WO2012143599A1 (en) 2011-04-21 2012-10-26 Orion Corporation Androgen receptor modulating carboxamides

Also Published As

Publication number Publication date
US20190321333A1 (en) 2019-10-24
US20180008577A1 (en) 2018-01-11
US10376494B2 (en) 2019-08-13
JP2018503662A (ja) 2018-02-08
HUE058986T2 (hu) 2022-09-28
DK3250554T3 (da) 2022-06-27
US10835515B2 (en) 2020-11-17
US20180280354A1 (en) 2018-10-04
US10010530B2 (en) 2018-07-03
CY1125482T1 (el) 2026-02-25
JP7283861B2 (ja) 2023-05-30
US10383853B2 (en) 2019-08-20
EP3250554A1 (en) 2017-12-06
WO2016120530A1 (en) 2016-08-04
ES2917549T3 (es) 2022-07-08
PL3250554T3 (pl) 2022-09-19
HRP20220998T1 (hr) 2022-11-11
LT3250554T (lt) 2022-06-10
PT3250554T (pt) 2022-06-02
RS63477B1 (sr) 2022-08-31
EP3250554B1 (en) 2022-05-18
JP2021020935A (ja) 2021-02-18
US20180280355A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
SI3250554T1 (sl) Derivat karboksiamida in njegovi diastereomeri v stabilni kristalinični obliki
IL280863A (en) Autotaxin inhibitors and uses thereof
KR20180084891A (ko) 구조 조성물 및 방법
PL3352776T3 (pl) Represory htt i ich zastosowanie
PL3265448T3 (pl) Proleki riluzolu i ich zastosowanie
DK3331877T3 (da) Pyrazolpyrimidinderivat og anvendelser deraf
DK3663292T3 (da) Diphenylmethan-derivat i krystallinsk form
LT3368534T (lt) Valbenazino ditozilatas ir jo polimorfai
LT2970256T (lt) Nauji oktahidro-pirolo[3,4-c]-pirolo dariniai ir jų analogai, kaip autotaksino inhibitoriai
DK3329378T3 (da) Adressecaching i switcher
EP3732091A4 (en) SHOVELS AND MACHINES WITH SHOVELS
PT3394259T (pt) Composições e métodos para diminuir a expressão de tau
PL3319612T3 (pl) Oksysterole i sposoby ich stosowania
PL3287443T3 (pl) 6-członowa pochodna heterocykliczna i kompozycja farmaceutyczna ją zawierająca
LT3606929T (lt) Beta-nikotinatinato esterio nukleotidai ir jų gamybos būdai
DK3212776T3 (da) Sammensætninger og fremgangsmåder i forbindelse med beta-glucosidase
DK3143018T3 (da) Carboxamidderivater
EP3309163A4 (en) SUBSTITUTED DIHYDROPYRROLO PYRAZOL DERIVATIVE
LT3347356T (lt) Tricikliniai sulieti piridin-2-ono dariniai ir jų naudojimas kaip brd4 inhibitorių
PL3337506T3 (pl) Kombinacje i ich zastosowania
DK3386956T3 (da) Fumagillolderivater og polymorfer deraf
SI3400217T1 (sl) L-valinat derivata hidroksipropiltiazolidin karboksamida, njegova sol in njegova kristalna oblika
EP3372589A4 (en) pyrimidine derivative
HUE054061T2 (hu) Viszko-elasztikus összetétel
EP3349748A4 (en) COMPOSITION AND METHOD THEREFOR